Environmental Scan Naloxone Access and Distribution in Canada
Bibliographic record
Abstract
In response to an epidemic of opioid overdose deaths attributed to prescription and illicit opioid use, distribution of the opioid antagonist naloxone has been identified in Canada and abroad as a key emergency measure to effectively prevent rising mortality (1,2). The current environmental scan was produced in order to better understand current practices and programs aimed to distribute naloxone for use in suspected opioid overdose, to assess uptake of these programs across Canadian provinces and territories (P/Ts), and to understand barriers related to knowledge and evidence in the use of naloxone, as well as operational obstacles to achieving widespread population coverage. Publicly funded take-home naloxone (THN) programs have been rolled out across every province and territory in Canada in response to the current opioid crisis. All publicly funded THN programs offer naloxone free of charge to those at risk of opioid overdose, while the majority of these programs also target any person who self-identifies as being at risk of witnessing an opioid overdose (including friends or family of people who use drugs). All provinces offer kits with the injectable formulation of naloxone as part of their publicly-funded program, while three P/Ts (Ontario, Quebec, and the Northwest Territories) also offer the nasal naloxone spray. Nasal naloxone spray is also available to clients of Veterans Affairs Canada, and through the NonInsured Health Benefits (NIHB) Program (benefits for First Nations individuals who present a valid status card and personal health number to confirm their eligibility). In most P/Ts, naloxone is made available through a number of different sites and organisations, including community pharmacies, shelters, medical centres, and treatment service centres, although some jurisdictions are limited in their ability to distribute naloxone due to geographical considerations and regulations related to provincial drug scheduling. While population access to naloxone has improved substantially across the country, there remain some jurisdiction-specific operational, geographic, knowledge/evidence, and policy barriers to access. Importantly, there are several unanswered questions regarding the safety and effectiveness of different naloxone routes of administration, dosing, and the extent of training needed to effectively respond to an overdose and administer naloxone. Evidence regarding the benefit of distributing naloxone broadly (as opposed to only specific at-risk populations) is needed. There are also ethical considerations including how to collect robust health data while protecting low-barrier access environments and respecting patient anonymity, and whether it is appropriate to provide naloxone kits to minors. Additional considerations include identifying the most effective overdose response strategy more generally (outlining actions to take beyond administering naloxone, such as chest compressions, rescue breaths, calling 911, etc., and the order to take them in), as well as in the development of program evaluation practices and performance indicators. Consolidating existing evidence, suggesting areas for future research, and building consensus among stakeholders may help improve naloxone access and ensure equitable outcomes in Canada. Finally, there is continued recognition of the complex social, political, and legal solutions needed to address the state of the opioid crisis in Canada, as well as for the need to address continued stigma around drug use, integrate harm reduction practices, and support a holistic model of care in order to best confront the upstream factors leading to overdose, addiction, and substance use.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.004 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.001 |
| Bibliometrics | 0.006 | 0.016 |
| Science and technology studies | 0.004 | 0.001 |
| Scholarly communication | 0.003 | 0.001 |
| Open science | 0.002 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.018 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".